



BLISS GVS PHARMA LIMITED

CIN: L24230MH1984PLC034771

Registered Office: 102, Hyde Park, Sakivihar Road, Andheri (East), Mumbai - 400 072.

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31.12.2014

PART - I		(Rs. in Lakhs)					
SR. No.	PARTICULARS	STANDALONE					
		QUARTER ENDED			NINE MONTHS ENDED		YEAR ENDED
		31.12.2014 (UNAUDITED)	30.09.2014 (UNAUDITED)	31.12.2013 (UNAUDITED)	31.12.2014 (UNAUDITED)	31.12.2013 (UNAUDITED)	31.03.2014 (AUDITED)
1	Income From Operations						
	(a) Net Sales (Net of Excise Duty)	8413.00	8755.69	5885.77	24149.57	22976.12	28349.25
	(b) Other Operating Income	168.29	173.72	114.98	448.12	520.59	696.43
	Total Income From Operations (Net)	8581.29	8929.41	6000.75	24597.69	23496.71	29045.68
2	Expenses						
	a) Consumption of Raw Materials	4041.61	4190.15	2,221.23	10,838.66	10,615.19	13517.82
	b) Purchase of Traded Goods	0.00	90.32	0.00	90.32	500.90	1030.40
	c) Changes in inventories of finished goods, work in progress, Stock in Trade	-150.56	17.62	165.13	135.17	429.95	60.57
	d) Employee Benefit Expenses	454.39	409.13	323.94	1257.70	952.13	1292.61
	e) Depreciation / Amortisation	131.34	118.48	128.04	362.75	374.59	446.16
	f) Other Expenditure	1791.28	1327.98	1355.59	4792.02	4883.16	6314.46
	Total Expenses	6268.06	6153.69	4193.93	17476.62	17755.92	22662.02
3	Profit From Operations Before Other Income & Finance Cost & Exceptional Items (1-2)	2313.23	2775.72	1806.82	7121.07	5740.79	6383.66
4	Other Income	798.26	713.38	145.46	1761.52	2699.80	2789.81
5	Profit From Ordinary Activities Before Finance Cost (3+4)	3111.49	3489.10	1952.28	8882.59	8440.59	9173.47
6	Finance Cost	349.61	251.17	220.86	824.76	634.19	943.63
7	Profit From Ordinary Activities After Finance Cost But Before Exceptional Items (5-6)	2761.88	3237.93	1731.42	8057.83	7806.40	8229.84
8	Exceptional Items	-	-	-	-	-	-
9	Profit From Ordinary Activities Before Tax (7-8)	2761.88	3237.93	1731.42	8057.83	7806.40	8229.84
10	Tax Expense (including Deferred Tax)	962.62	1081.20	668.58	2702.39	2565.19	2837.19
11	Net Profit After Tax For The Period (9 - 10)	1799.26	2156.73	1062.84	5355.44	5241.21	5392.65
12	Paid - Up Equity Capital	1031.47	1031.47	1031.47	1031.47	1031.47	1031.47
13	Reserves Excluding Revaluation Reserve (as Per Balance Sheet)	-	-	-	-	-	30452.64
14	Basic and Diluted Eps (not Annualised)	1.74	2.09	1.03	5.19	5.08	5.23
PART - II							
A	Particulars of Shareholding						
1	Aggregate of Non-promoter Shareholding						
	- No. of Shares (Face Value Rs. 1/- Each)	36156842	36156842	36156842	36156842	36156842	36156842
	- Percentage of Shareholding (%)	35.05	35.05	35.05	35.05	35.05	35.05
2	Promoter and Promoter Group Shareholding						
	A) Pledge/ Encumbered						
	- No. of Shares (Face Value Re. 1/- Each)	-	-	-	-	-	-
	- Percentage of Shares (As % of the total Share Holding of Promoter & Promoter Group)	-	-	-	-	-	-
	- Percentage of Shares (As % of the total Share Capital of The Company)	-	-	-	-	-	-
	B) Non - Encumbered						
	- No. of Shares (Face Value Re. 1/- Each)	66989830	66989830	66989830	66989830	66989830	66989830
	- Percentage of Shares (As % of the total Share Holding of Promoter & Promoter Group)	100.00	100.00	100.00	100.00	100.00	100.00
	- Percentage of Shares (As % of the total Share Capital of The Company)	64.95	64.95	64.95	64.95	64.95	64.95
	PARTICULARS	Quarter ended 31 December 2014					
B	INVESTOR COMPLAINTS						
	Pending at the beginning of the quarter				-		
	Received during the quarter				2		
	Disposed off during the quarter				2		
	REMAINING UNSOLVED AT THE END OF THE QUARTER				-		

Notes:-

- The Company operates primarily in the pharmaceutical business and hence has only one reportable segment.
- During the quarter the Company has formed a subsidiary in United Kingdom with 100% stake in the name of Asterisk Lifesciences Ltd.
- The above results were reviewed by the audit committee & were there after approved by the Board at its meeting held on 12th February, 2015
- The statutory auditors have carried out "Limited Review" of the aforesaid results for the quarter ended December 31, 2014.
- Figures for the previous periods have been regrouped/rearranged wherever necessary.
- Depreciation for the quarter is based on the Schedule II of the Companies Act 2013 which is effective from April 1, 2014. This has resulted in a net additional depreciation of Rs 28.28 lacs being charged to the statement of profit & loss during the quarter. Further, assets whose useful life has expired as on April 1, 2014 the entire carrying value of that date has been recognised in the opening balance of retained earnings as specified in the Schedule II of the Companies Act, 2013.
- The board has recommended an interim dividend of 20% i.e. Re. 0.20 per equity share for the year 2014-2015.

FOR BLISS GVS PHARMA LIMITED

SD/-

S. N. KAMATH
MANAGING DIRECTOR

Place : Mumbai
Date : 12th February'2015